for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bristol-Myers Squibb Co

BMY.N

Latest Trade

56.41USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

42.49

 - 

59.17

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
56.41
Open
--
Volume
--
3M AVG Volume
249.77
Today's High
--
Today's Low
--
52 Week High
59.17
52 Week Low
42.49
Shares Out (MIL)
1,629.00
Market Cap (MIL)
92,022.01
Forward P/E
13.00
Dividend (Yield %)
2.90

Next Event

Q4 2019 Bristol-Myers Squibb Co Earnings Release

Latest Developments

More

Bristol-Myers Squibb Co Says It Expects No Further Extension Of Expiration Date For Exchange Offers For Celgene Corp Notes

Bristol-Myers Squibb Receives Clearance From U.S. FTC For Celgene Acquisition

U.S. FDA Accepts For Priority Review Bristol-Myers Squibb’s Application For Opdivo

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bristol-Myers Squibb Co

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.

Industry

Biotechnology & Drugs

Contact Info

430 E 29th St Fl 14

+1.212.5464000

https://www.bms.com/

Executive Leadership

Giovanni Caforio

Chairman of the Board, Chief Executive Officer

Charles A. Bancroft

Chief Financial Officer, Executive Vice President - Global Business Operations

Ann Powell Judge

Chief Human Resource Officer, Senior Vice President

Sandra Leung

Executive Vice President, General Counsel

Christopher S. Boerner

Executive Vice President and Chief Commercial Officer

Key Stats

2.00 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

19.4K

2017

20.8K

2018

22.6K

2019(E)

24.3K
EPS (USD)

2016

2.830

2017

3.010

2018

3.980

2019(E)

4.343
Price To Earnings (TTM)
16.32
Price To Sales (TTM)
3.81
Price To Book (MRQ)
5.21
Price To Cash Flow (TTM)
14.31
Total Debt To Equity (MRQ)
141.43
LT Debt To Equity (MRQ)
138.20
Return on Investment (TTM)
16.07
Return on Equity (TTM)
12.47

Latest News

Latest News

Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug

Amgen Inc <AMGN.O> on Thursday raised its full-year profit and revenue forecasts after completing its $13.4 billion acquisition of Celgene Corp's psoriasis therapy Otezla.

Bristol-Myers misses main goal of late-stage skin cancer trial

Bristol-Myers Squibb Co said on Wednesday a late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients, sending its shares down nearly 1%.

Bristol-Myers misses main goal of late-stage skin cancer trial

Bristol-Myers Squibb Co said on Wednesday its late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients.

Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday.

Bristol-Myers Squibb wins antitrust approval to buy Celgene on condition it sell psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday. (Reporting by Diane Bartz; Editing by Sandra Maler)

Bristol-Myers posts better-than-expected results, Opdivo growth slows

U.S. drugmaker Bristol-Myers Squibb Co <BMY.N> reported higher-than-expected third-quarter profit on Thursday, helped by strong sales of blood thinner Eliquis, even as growth of its blockbuster cancer treatment Opdivo slowed.

Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise

Bristol-Myers Squibb Co said on Tuesday an interim analysis of a late-stage trial testing a combination of its immuno-oncology drugs Opdivo and Yervoy met the main goal of extending life of previously untreated lung cancer patients.

Bristol-Myers immunotherapy combo outperforms chemo in lung cancer survival: study

About 40% of patients who received a combination of Bristol-Myers Squibb Co's immuno-oncology drugs Opdivo and Yervoy as an initial treatment for advanced non-small cell lung cancer (NSCLC) were alive after two years, according to data presented at a medical meeting on Saturday...

UPDATE 1-Bristol-Myers' Opdivo fails to meet goal of brain tumor study

Bristol-Myers Squibb Co said on Thursday its blockbuster cancer immunotherapy, Opdivo, failed to meet the main goal of a late-stage trial testing it in patients with a type of tumor that affects the brain and spine.

Amgen to buy Celgene's psoriasis drug Otezla for $13.4 bln in cash

Amgen Inc said on Monday it would buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene.

Eliquis, Orencia sales propel Bristol-Myers to strong second quarter

Bristol-Myers Squibb Co <BMY.N>, which is set to buy biotechnology company Celgene Corp <CELG.O> for $74 billion, posted better-than-expected second-quarter profit on Thursday on strong sales of blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise

Bristol-Myers Squibb, which is set to buy biotechnology company Celgene Corp soon for $74 billion, posted better-than-expected second-quarter earnings on Thursday on strong sales from its blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

Bristol-Myers releases mixed Opdivo lung cancer results

Bristol-Myers Squibb Co released mixed results on Wednesday from trials testing the survival benefit of its immunotherapy Opdivo in combination with either chemotherapy or its other immuno-oncology drug, Yervoy, as an initial treatment for advanced lung cancer.

Bristol-Myers plans to divest Celgene's psoriasis drug

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

Bristol to divest Celgene's psoriasis treatment in FTC clearance push

Bristol-Myers Squibb Co said on Monday it would divest Celgene Corp's psoriasis treatment Otezla as the companies look to gain approval for their $74 billion deal from the U.S. Federal Trade Commission (FTC).

Bristol-Myers' Opdivo fails late-stage brain cancer trial

Bristol-Myers Squibb Co said on Thursday its immunotherapy Opdivo failed to meet the main goal of a late-stage trial testing it in patients with an aggressive form of tumor that affects the brain or the spine.

Puerto Rico board files flurry of lawsuits ahead of claim deadline

Puerto Rico's federally created financial oversight board on Tuesday began filing the first round of scores of lawsuits seeking to recover money the bankrupt U.S. commonwealth paid to bondholders, businesses and others.

Bristol-Myers profit slightly tops Wall Street view on blood thinner sales

U.S drugmaker Bristol-Myers Squibb Co, which is set to buy biotechnology company Celgene Corp for $74 billion, posted slightly better-than-expected first-quarter earnings on Thursday on strong sales of its blockbuster blood thinner Eliquis.

Bristol-Myers says shareholders vote to approve Celgene takeover

Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion acquisition of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Bristol-Myers says shareholders vote to approve Celgene takeover

Bristol-Myers Squibb Inc's shareholders voted to approve the drugmaker's $74 billion takeover of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up